<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03856164</url>
  </required_header>
  <id_info>
    <org_study_id>STU-2018-0315</org_study_id>
    <nct_id>NCT03856164</nct_id>
  </id_info>
  <brief_title>Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery</brief_title>
  <acronym>TXA</acronym>
  <official_title>Use of Tranexamic Acid for Prevention of Hemorrhage in Cesarean Delivery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators prepared a novel study of tranexamic acid (TXA) designed to estimate the
      quantity of blood loss in women undergoing elective repeat cesarean deliveries. This is the
      first trial to utilize a prophylactic dose of TXA prior to incision followed by a subsequent
      prophylactic dose at placental delivery in obstetric patients undergoing scheduled cesareans.
      The purpose of this study is to quantify blood loss during uncomplicated repeat cesarean
      deliveries with and without TXA. The central hypothesis is that TXA administration reduces
      blood loss and fibrinolysis in women undergoing repeat cesarean sections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obstetric hemorrhage has been identified as a contributory cause for the United States'
      suboptimal and inequitable outcomes among pregnant women. As such, obstetric hemorrhage has
      become a formal focus point in a national agenda to improve maternal outcomes. Strategies to
      identify maternal hypovolemia and treating obstetric hemorrhage are undergoing organized
      scrutiny in many states including Texas. Tranexamic acid (TXA) treatment is receiving
      increased emphasis in obstetric care because TXA inhibits fibrinolysis. Increased clot
      stability offers the possibility of preventing blood loss (prophylaxis) as well as mitigating
      ongoing hemorrhage. TXA therapy has been principally studied in nonpregnant populations;
      results of studies in pregnant women have been lacking.

      Tranexamic acid is an antifibrinolytic agent that acts as a competitive inhibitor at the
      lysine binding sites of plasminogen and inhibits the ability of protease plasmin to cleave
      the fibrin clot. In large randomized controlled trials, it has been reported to be effective
      in decreasing perioperative blood loss in a variety of circumstances primarily involving
      trauma patients. Shakur and co-authors in a trial of 20,000 non-pregnant trauma patients
      reported a significant reduction in all-cause mortality after TXA administration. In another
      large study (WOMAN Trial), 20,000 pregnant women with hemorrhage were randomized to TXA or
      placebo. TXA was associated with a significant decrease in death due to bleeding.

      Tranexamic acid's role in treating hemorrhage have been widely studied in non-pregnant
      populations. Studies of TXA in obstetrics are limited. The American College of Obstetricians
      and Gynecologists believes the data is insufficient to recommend tranexamic acid for
      prophylaxis.

      The investigators designed a randomized placebo-controlled trial comparing TXA dosing prior
      to incision for cesarean delivery with a repeat dose given at placental delivery. The purpose
      is to quantify blood loss during uncomplicated repeat cesarean deliveries with and without
      TXA. The investigators elected to study scheduled elective cesareans because such procedures
      are at low risk for profound hemorrhage. It is the intent to have a study cohort where the
      two treatment groups (TXA or placebo) are as comparable as possible, so the efficacy of TXA
      is not tested in women with highly variable volumes of obstetric hemorrhage.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 17, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Actual">June 10, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Blood volume loss</measure>
    <time_frame>24 hours postpartum.</time_frame>
    <description>Total blood volume lost will be calculated in milliliters.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fibrinogen (mg/dL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Blood sample collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-Dimer (mcg/mL fibrinogen equivalent units)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Blood sample collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Plasminogen Activator Antigen (ng/mL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Blood sample collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasminogen Activator Inhibitor-Type-1 (Units/mL)</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Blood sample collected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rotational Thromboelastometry (ROTEM) Values</measure>
    <time_frame>Collection prior to first drug infusion, immediately before second infusion and 24 hours postpartum.</time_frame>
    <description>Blood sample collected.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Post Partum Hemorrhage</condition>
  <condition>Fibrinolysis; Hemorrhage</condition>
  <condition>Blood Loss</condition>
  <arm_group>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tranexamic Acid for intravenous administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline for intravenous administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid</intervention_name>
    <description>Two doses of Tranexamic Acid (1 gram), diluted in 100 cc of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
    <arm_group_label>Tranexamic acid</arm_group_label>
    <other_name>Cyklokapron</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100 mL of normal saline. Administered intravenously at least 10 minutes prior to skin incision and repeated immediately after placental delivery.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Normal Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Intrauterine pregnancy

          2. Age ≥ 18

          3. Gestation age ≥ 37 weeks 0 days

          4. Scheduled cesarean delivery

          5. Second or third cesarean delivery

          6. Singleton pregnancy

        Exclusion Criteria:

          1. First cesarean delivery

          2. Four or more cesarean deliveries

          3. Intrauterine fetal death

          4. Fetal anomalies

          5. Documented coagulopathy (Elevated Prothrombin Time (PT), Elevated Partial
             Thromboplastin Time (PTT), Elevated International Normalized Ratio (INR))

          6. Thrombocytopenia (Platelet count &lt; 100k)

          7. Internal bleeding, external bleeding, easy bruising

          8. History of thrombotic event

          9. Hypertension

         10. Diagnosis of renal insufficiency (Creatinine&gt; 1 mg/dL)

         11. Insulin-treated diabetes

         12. Suspected morbidly adherent placenta

         13. Placenta previa

         14. Multiple Gestations

         15. BMI ≥ 50

         16. Hematocrit ≤ 25

         17. Blood transfusion within 24 hours prior to cesarean delivery

         18. History of abnormal bleeding or blood disorder

         19. Planned general anesthesia
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olutoyosi Ogunkua, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Hospital</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>American Society of Anesthesiologists Task Force on Perioperative Blood Management. Practice guidelines for perioperative blood management: an updated report by the American Society of Anesthesiologists Task Force on Perioperative Blood Management*. Anesthesiology. 2015 Feb;122(2):241-75. doi: 10.1097/ALN.0000000000000463. Review.</citation>
    <PMID>25545654</PMID>
  </reference>
  <reference>
    <citation>WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage. Geneva: World Health Organization; 2012.</citation>
    <PMID>23586122</PMID>
  </reference>
  <reference>
    <citation>Carroli G, Cuesta C, Abalos E, Gulmezoglu AM. Epidemiology of postpartum haemorrhage: a systematic review. Best Pract Res Clin Obstet Gynaecol. 2008 Dec;22(6):999-1012. doi: 10.1016/j.bpobgyn.2008.08.004. Epub 2008 Sep 25. Review.</citation>
    <PMID>18819848</PMID>
  </reference>
  <reference>
    <citation>GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1775-1812. doi: 10.1016/S0140-6736(16)31470-2. Erratum in: Lancet. 2017 Jan 7;389(10064):e1.</citation>
    <PMID>27733286</PMID>
  </reference>
  <reference>
    <citation>WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy, and other morbidities in women with post-partum haemorrhage (WOMAN): an international, randomised, double-blind, placebo-controlled trial. Lancet. 2017 May 27;389(10084):2105-2116. doi: 10.1016/S0140-6736(17)30638-4. Epub 2017 Apr 26. Erratum in: Lancet. 2017 May 27;389(10084):2104.</citation>
    <PMID>28456509</PMID>
  </reference>
  <reference>
    <citation>Committee on Practice Bulletins-Obstetrics. Practice Bulletin No. 183: Postpartum Hemorrhage. Obstet Gynecol. 2017 Oct;130(4):e168-e186. doi: 10.1097/AOG.0000000000002351.</citation>
    <PMID>28937571</PMID>
  </reference>
  <reference>
    <citation>Ducloy-Bouthors AS, Jeanpierre E, Saidi I, Baptiste AS, Simon E, Lannoy D, Duhamel A, Allorge D, Susen S, Hennart B. TRAnexamic acid in hemorrhagic CESarean section (TRACES) randomized placebo controlled dose-ranging pharmacobiological ancillary trial: study protocol for a randomized controlled trial. Trials. 2018 Mar 1;19(1):149. doi: 10.1186/s13063-017-2421-6.</citation>
    <PMID>29490690</PMID>
  </reference>
  <reference>
    <citation>Dunn CJ, Goa KL. Tranexamic acid: a review of its use in surgery and other indications. Drugs. 1999 Jun;57(6):1005-32. Review.</citation>
    <PMID>10400410</PMID>
  </reference>
  <reference>
    <citation>Hernandez JS, Alexander JM, Sarode R, McIntire DD, Leveno KJ. Calculated blood loss in severe obstetric hemorrhage and its relation to body mass index. Am J Perinatol. 2012 Aug;29(7):557-60. doi: 10.1055/s-0032-1310528. Epub 2012 Apr 11.</citation>
    <PMID>22495893</PMID>
  </reference>
  <reference>
    <citation>Huissoud C, Carrabin N, Audibert F, Levrat A, Massignon D, Berland M, Rudigoz RC. Bedside assessment of fibrinogen level in postpartum haemorrhage by thrombelastometry. BJOG. 2009 Jul;116(8):1097-102. doi: 10.1111/j.1471-0528.2009.02187.x. Epub 2009 May 12.</citation>
    <PMID>19459866</PMID>
  </reference>
  <reference>
    <citation>Khan KS, Wojdyla D, Say L, Gülmezoglu AM, Van Look PF. WHO analysis of causes of maternal death: a systematic review. Lancet. 2006 Apr 1;367(9516):1066-1074. doi: 10.1016/S0140-6736(06)68397-9. Review.</citation>
    <PMID>16581405</PMID>
  </reference>
  <reference>
    <citation>Main EK, Goffman D, Scavone BM, Low LK, Bingham D, Fontaine PL, Gorlin JB, Lagrew DC, Levy BS; National Partnership for Maternal Safety; Council on Patient Safety in Women's Health Care. National Partnership for Maternal Safety: Consensus Bundle on Obstetric Hemorrhage. Obstet Gynecol. 2015 Jul;126(1):155-62. doi: 10.1097/AOG.0000000000000869. Erratum in: Obstet Gynecol. 2015 Nov;126(5):1111. Obstet Gynecol. 2019 Jun;133(6):1287.</citation>
    <PMID>26241269</PMID>
  </reference>
  <reference>
    <citation>McCormack PL. Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs. 2012 Mar 26;72(5):585-617. doi: 10.2165/11209070-000000000-00000. Review.</citation>
    <PMID>22397329</PMID>
  </reference>
  <reference>
    <citation>Molina RL, Pace LE. A Renewed Focus on Maternal Health in the United States. N Engl J Med. 2017 Nov 2;377(18):1705-1707. doi: 10.1056/NEJMp1709473.</citation>
    <PMID>29091560</PMID>
  </reference>
  <reference>
    <citation>Say L, Chou D, Gemmill A, Tunçalp Ö, Moller AB, Daniels J, Gülmezoglu AM, Temmerman M, Alkema L. Global causes of maternal death: a WHO systematic analysis. Lancet Glob Health. 2014 Jun;2(6):e323-33. doi: 10.1016/S2214-109X(14)70227-X. Epub 2014 May 5. Review.</citation>
    <PMID>25103301</PMID>
  </reference>
  <reference>
    <citation>John M. Eisenberg Center for Clinical Decisions and Communications Science. Management of Postpartum Hemorrhage: Current State of the Evidence. 2016 Jul 12. Comparative Effectiveness Review Summary Guides for Clinicians [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007-. Available from http://www.ncbi.nlm.nih.gov/books/NBK379234/</citation>
    <PMID>27512800</PMID>
  </reference>
  <reference>
    <citation>Sentilhes L, Winer N, Azria E, Sénat MV, Le Ray C, Vardon D, Perrotin F, Desbrière R, Fuchs F, Kayem G, Ducarme G, Doret-Dion M, Huissoud C, Bohec C, Deruelle P, Darsonval A, Chrétien JM, Seco A, Daniel V, Deneux-Tharaux C; Groupe de Recherche en Obstétrique et Gynécologie. Tranexamic Acid for the Prevention of Blood Loss after Vaginal Delivery. N Engl J Med. 2018 Aug 23;379(8):731-742. doi: 10.1056/NEJMoa1800942.</citation>
    <PMID>30134136</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 27, 2019</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Olutoyosi Ogunkua</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>Tranexamic acid</keyword>
  <keyword>TXA</keyword>
  <keyword>Anti-fibrinolytics</keyword>
  <keyword>Postpartum hemorrhage</keyword>
  <keyword>Obstetric hemorrhage</keyword>
  <keyword>Fibrinolysis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postpartum Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

